STOCK TITAN

Horizon Therapeutics Plc - HZNP STOCK NEWS

Welcome to our dedicated page for Horizon Therapeutics Plc news (Ticker: HZNP), a resource for investors and traders seeking the latest updates and insights on Horizon Therapeutics Plc stock.

Horizon Therapeutics plc (NASDAQ: HZNP) is a global biotechnology company dedicated to the discovery, development, and commercialization of medicines for rare, autoimmune, and severe inflammatory diseases. Horizon’s mission is to blend science and compassion to transform the lives of patients who are often underserved. The company’s therapeutic portfolio includes innovative products such as TEPEZZA® (teprotumumab-trbw) and KRYSTEXXA® (pegloticase injection), which address critical medical needs.

Horizon is driven by a deep understanding of the patient journey and aims to bring clinically meaningful therapies to those who need them most. The company is heavily invested in scientific research and development, and this commitment is evident in its robust pipeline of medicines designed to address complex medical conditions.

Recently, Horizon entered into a consent order agreement with the Federal Trade Commission (FTC) to resolve a pending administrative lawsuit, clearing the way for its acquisition by Amgen (NASDAQ: AMGN). This deal is expected to close in early fourth-quarter 2023, pending final approvals. Amgen, a pioneer in biotechnology, is committed to advancing human therapeutics and has been recognized as one of “America’s Greatest Workplaces” by Newsweek and one of “America’s Climate Leaders” by USA Today.

Horizon’s commitment to combining scientific expertise with compassionate care sets it apart in the biotech industry. By focusing on areas of high unmet medical need, Horizon aims to deliver breakthrough therapies that can improve health outcomes and dramatically enhance the quality of life for patients around the world.

For more information on Horizon and its groundbreaking work, visit its official website at HorizonTherapeutics.com and follow the company on social media platforms such as Twitter, LinkedIn, Instagram, and Facebook.

Rhea-AI Summary
Horizon Therapeutics announces date of Court Hearing for recommended cash offer by Pillartree Limited, a wholly owned subsidiary of Amgen Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
none
-
Rhea-AI Summary
Amgen and Horizon Therapeutics resolve pending FTC lawsuit, clearing the way for Amgen's acquisition of Horizon
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
-
Rhea-AI Summary
Amgen and Horizon Therapeutics resolve pending FTC lawsuit, clearing path for acquisition
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
Rhea-AI Summary
Horizon Therapeutics ranks first in overall corporate reputation among rare disease patient groups worldwide, according to PatientView's survey. They also ranked first in 10 indicators including patient centricity and access to medicines. 91 rare disease patient advocacy groups were familiar with Horizon and 59 worked with the company. Horizon's global expansion and collaboration with patient advocacy groups contribute to their positive reputation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
none
-
Rhea-AI Summary
Horizon Therapeutics announces second-quarter 2023 financial results with net sales of $945.0 million, representing 11% YoY growth excluding inflammation medicines. The company reports GAAP net income of $127.1 million and adjusted EBITDA of $320.4 million. TEPEZZA, KRYSTEXXA, and UPLIZNA contribute to strong sales growth. Cash position is $2.5 billion as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.91%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
none
-
Rhea-AI Summary
HZNP: Horizon Therapeutics Announces 50 Awardees for 2023 #RAREis Global Advocate Grant, Awarding $5,000 to Rare Disease Patient Advocacy Organizations
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
none
-
Rhea-AI Summary
Horizon Therapeutics announced that its Phase 2 clinical trial evaluating daxdilimab for the treatment of SLE did not show a statistically significant separation between daxdilimab and placebo on the primary endpoint. Numerical differences were seen in other endpoints and no safety concerns were reported.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.77%
Tags
Rhea-AI Summary
HZNP: Horizon Therapeutics to Release Q2 2023 Financial Results, No Conference Call Due to Pending Amgen Inc. Acquisition
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.06%
Tags

FAQ

What is Horizon Therapeutics?

Horizon Therapeutics is a global biotechnology company focused on developing medicines for rare, autoimmune, and severe inflammatory diseases.

What products does Horizon Therapeutics offer?

Horizon offers innovative products like TEPEZZA® and KRYSTEXXA®, aimed at addressing critical medical needs.

What recent achievements has Horizon Therapeutics made?

Horizon has entered into a consent order agreement with the FTC, paving the way for its acquisition by Amgen, expected to close in early fourth-quarter 2023.

Who is acquiring Horizon Therapeutics?

Amgen, a leading biotechnology company, is set to acquire Horizon Therapeutics.

How is Horizon Therapeutics contributing to medical science?

Horizon is dedicated to developing clinically meaningful therapies for rare, autoimmune, and severe inflammatory diseases, leveraging scientific research and patient-focused care.

What is the mission of Horizon Therapeutics?

Horizon aims to transform lives by delivering innovative medicines and combining science with compassion to meet unmet medical needs.

How can I learn more about Horizon Therapeutics?

Visit Horizon's official website at HorizonTherapeutics.com for more information, or follow them on social media platforms like Twitter, LinkedIn, Instagram, and Facebook.

What is the significance of Horizon’s recent agreement with the FTC?

The agreement with the FTC resolves a pending administrative lawsuit, allowing Horizon's acquisition by Amgen to proceed.

Where is Horizon Therapeutics headquartered?

Horizon Therapeutics is headquartered in Dublin, Ireland, but operates globally.

What is the focus of Horizon's research and development efforts?

Horizon focuses on developing treatments for rare, autoimmune, and severe inflammatory diseases, aiming to meet high unmet medical needs.

Horizon Therapeutics Plc

Nasdaq:HZNP

HZNP Rankings

HZNP Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link